on May 31, 2007
Published online before print May 31, 2007, doi: 10.1161/ATVBAHA.107.142943
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 25, 2007
Accepted on May 14, 2007
Nitric Oxide in the Pulmonary Vasculature
Matthew P. Coggins * and Kenneth D. Bloch
From the Cardiology Division of the Department of Medicine and the Department of Anesthesia and Critical Care, Massachusetts General Hospital, Boston.
* To whom correspondence should be addressed. E-mail: mcoggins{at}partners.org.
Abstract--Homeostasis in the pulmonary vasculature is maintained by the actions of vasoactive compounds, including nitric oxide (NO). NO is critical for normal development of the pulmonary vasculature and continues to mediate normal vasoregulation in adulthood. Loss of NO bioavailability is one component of the endothelial dysfunction and vascular pathology found in pulmonary hypertension (PH). A broad research effort continues to expand our understanding of the control of NO production and NO signaling and has generated novel theories on the importance of pulmonary NO production in the control of the systemic vasculature. This understanding has led to exciting developments in our ability to treat PH, including inhaled nitric oxide and phosphodiesterase inhibitors, and to several promising directions for future therapies using nitric oxide-donor compounds, activators of soluble guanylate cyclase, progenitor cells, and NOS gene manipulation.
Key words: nitric oxide • pulmonary vasculature • pulmonary hypertension treatment
This article has been cited by other articles:
 |
|
 |
|
  B. Vollmar and M. D. Menger The Hepatic Microcirculation: Mechanistic Contributions and Therapeutic Targets in Liver Injury and Repair Physiol Rev, October 1, 2009; 89(4): 1269 - 1339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lee, R. Reich, F. Xu, and P. B. Sehgal Golgi, trafficking, and mitosis dysfunctions in pulmonary arterial endothelial cells exposed to monocrotaline pyrrole and NO scavenging Am J Physiol Lung Cell Mol Physiol, October 1, 2009; 297(4): L715 - L728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yamazato, A. J. Ferreira, K.-H. Hong, S. Sriramula, J. Francis, M. Yamazato, L. Yuan, C. N. Bradford, V. Shenoy, S. P. Oh, et al. Prevention of Pulmonary Hypertension by Angiotensin-Converting Enzyme 2 Gene Transfer Hypertension, August 1, 2009; 54(2): 365 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zoccali, C. Catalano, and S. Rastelli Blood pressure control: hydrogen sulfide, a new gasotransmitter, takes stage Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1394 - 1396. [Full Text] [PDF]
|
|
|
|
|
|
J. G. Lopez-Lopez, J. Moral-Sanz, G. Frazziano, M. J. Gomez-Villalobos, J. Flores-Hernandez, E. Monjaraz, A. Cogolludo, and F. Perez-Vizcaino Diabetes induces pulmonary artery endothelial dysfunction by NADPH oxidase induction Am J Physiol Lung Cell Mol Physiol, November 1, 2008; 295(5): L727 - L732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-J. Lai, S. S. Pullamsetti, E. Dony, N. Weissmann, G. Butrous, G.-A. Banat, H. A. Ghofrani, W. Seeger, F. Grimminger, and R. T. Schermuly Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension Am. J. Respir. Crit. Care Med., July 15, 2008; 178(2): 188 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Frank, J. Lowery, L. Anderson, M. Brink, J. Reese, and M. de Caestecker Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature Am J Physiol Lung Cell Mol Physiol, January 1, 2008; 294(1): L98 - L109. [Abstract] [Full Text] [PDF]
|
|